ReviewInternational urology and nephrology2021
Rezum: a novel minimally invasive treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. A review article.
Review in International urology and nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 16 citations in OpenAlex.
- Factors predicting the success of ejaculation preserving transurethral resection of the prostate: a prospective cohort study.Prostate international · 2026Article
- Four-year outcomes of water vapor thermal therapy for benign prostatic hyperplasia.Prostate international · 2026Article
- A comparative analysis of the outcomes of Rezūm therapy based on prostate size: a four-year retrospective analysis.World journal of urology · 2025Article
- Real-world four-year functional and surgical outcomes of Rezum therapy in younger versus elderly men.Prostate cancer and prostatic diseases · 2024Article
- Water vapor therapy and polymyalgia rheumatica: Coincidental?Journal of family medicine and primary care · 2023Article
- Short course of dutasteride in treatment of a refractory category IIIB chronic prostatitis (A placebo-controlled study).Prostate international · 2022Article
- Letter to the Editor-Rezūm for benign prostatic hyperplasia: no or low rates of post-operative ejaculatory dysfunction?International urology and nephrology · 2022Article
- Transperineal ultrasound beyond prostate biopsy: pictorial essay.Radiologia brasileiraArticle
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) are one of the most common morbidities in elderly men, especially in aging societies. Minimally invasive surgical treatments (MISTs) for BPH have gained an increasing interest in the current time. Rezum system is a novel MIST that uses water vapour-based convective thermal therapy to ablate prostatic tissue. According to our evaluation of the existing literature, Rezum offers a meaningful relief of LUTS with a high safety profile without compromising the sexual activity especially to those who are unfit for surgery or to those who do not desire to continue on lifelong pharmacotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.